Is Allegra (fexofenadine) safe to use during pregnancy?

Is Allegra (Fexofenadine) Safe in Pregnancy?

Fexofenadine can be used during pregnancy, as it has demonstrated safety comparable to other second-generation antihistamines with no increased risk of major birth defects, spontaneous abortion, or other adverse fetal outcomes. 1, 2

Evidence Supporting Safety

Human Pregnancy Data

• A large Danish nationwide cohort study (2020) of nearly 1.3 million pregnancies found no association between fexofenadine use and adverse fetal outcomes when compared to cetirizine use during pregnancy 2
  • No increased risk of major birth defects (4.0% vs 3.8%; prevalence OR 1.06,95% CI 0.81-1.37) 2
  • No increased risk of spontaneous abortion (8.4% vs 9.0%; HR 0.93,95% CI 0.82-1.07) 2
  • No increased risk of preterm birth, small for gestational age, or stillbirth 2

Animal Studies and Historical Context

• Animal reproductive studies with fexofenadine are negative for teratogenicity 1
• The Journal of Allergy and Clinical Immunology guidelines note that while no epidemiologic studies in human pregnancy had been published at the time of their 2008 publication, there were no reports of increased congenital malformations with fexofenadine use 1

Clinical Context and Recommendations

Second-Generation Antihistamines as Preferred Agents

• Second-generation antihistamines now have accumulated sufficient human observational data demonstrating safety comparable to first-generation antihistamines 1
• Second-generation antihistamines are preferable to first-generation agents due to lack of sedative and impaired performance characteristics 1
• First-generation antihistamines like diphenhydramine have been associated with cleft palate development in some studies, though this remains controversial 1

Timing Considerations

• The first trimester is the most critical period for concern about congenital malformations due to organogenesis 1
• However, the large cohort study demonstrated safety across all trimesters of pregnancy 2

Important Caveats

Limited Historical Data

• At the time of major guideline publications (2008), there was acknowledgment that epidemiologic studies in human pregnancy were lacking for fexofenadine 1
• The 2020 Danish study has now filled this evidence gap with robust data from nearly 3,000 pregnancies with fexofenadine exposure 2

Placental Transfer

• Fexofenadine demonstrates low transplacental transfer (~16%), which is non-enantioselective and not influenced by drug interactions 3
• This limited placental passage provides additional reassurance regarding fetal safety 3

Comparison with Other Antihistamines

• Loratadine and cetirizine are classified as FDA Pregnancy Category B drugs with established safety profiles 4
• The Danish study used cetirizine as the comparator and found equivalent safety with fexofenadine 2
• Hydroxyzine should be used cautiously during the first trimester based on animal data 1

Practical Application

When treating allergic conditions during pregnancy, fexofenadine represents a safe and effective option that does not require avoidance or special precautions beyond standard dosing 2. The medication can be continued throughout pregnancy if needed for maternal symptom control, as untreated allergic conditions may negatively impact maternal quality of life without providing any benefit to the fetus 5.